Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Epix MS-325 User Fee Goal Is Oct. 15; Broad Vascular Imaging Claim Sought

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

FDA’s decision to assign Epix’s vascular imaging agent MS-325 a standard review sets the user fee goal for the NDA at Oct. 15.

You may also be interested in...



Schering AG/Epix Imaging Agent Requires Additional Clinical Studies – FDA

Schering AG/Epix MS-325 imaging agent requires additional clinical studies, FDA says in “approvable” letter. Outstanding questions relate to the non-contrast comparator scanning methods used in Phase III trials and statistical treatment of uninterpretable baseline scans

FDA Priority Review Voucher Redemption Fee Set At $4.6 Million In FY 2011

Redeeming a priority review voucher obtained by developing a drug for a tropical disease will cost companies $6.1 million in fiscal 2011

Topics

UsernamePublicRestriction

Register

MT142539

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel